Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib and Bevacizumab in PS 2 Advanced NSCLC
NCT00367601Phase 2Completed
- Start
- Aug 2006
- Primary completion
- Apr 2008
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib and bevacizumab in non-small cell lung cancer (NSCLC). Primary endpoint: Rate of Non-progressive Disease at 4 Months. Started Aug 2006; status: completed.
02
Drugs
erlotinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00367601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00367601.